Skip to main content
Signal8

VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets

$VNRXPress releaseMay 27, 2026, 8:17 AM ETRead the release

VolitionRx reported Q1 2026 revenue of $1 million, representing a 300% year-over-year increase, signaling accelerating commercial adoption. The company submitted a manuscript for its Nu.Q Vet feline cancer test, which could unlock a $5 million milestone payment upon publication, and is actively discussing licensing deals with more than a dozen global diagnostic leaders.

Key figures

Revenue
1000000
Revenue Yoy
300%
Vet tam
$1.0+ billion
Sepsis tam
$3.8 billion
Capture seq tam
$23 billion
Detecseps program value
$7.3 million
Feline milestone payment
$5 million
Total addressable market
$27+ billion
Feline lymphoma sensitivity
86%
Feline lymphoma specificity
97%
Early stage cancer sensitivity
95%
Early stage cancer specificity
95%

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.